Publicação
ANTI-VEGF therapies in neovascular age-related macular degeneration: a scoping review of functional and morphological outcomes in older adults
| dc.contributor.author | Queirós, Marta | |
| dc.contributor.author | Teixeira, Daniela | |
| dc.contributor.author | Jesus, Ângelo | |
| dc.contributor.author | Santos, Marlene | |
| dc.contributor.author | Moreira, Fernando | |
| dc.contributor.author | Fernandes, Sara R. | |
| dc.contributor.author | Santos, Marlene | |
| dc.contributor.author | Moreira, Fernando | |
| dc.contributor.author | Fernandes, Sara | |
| dc.date.accessioned | 2026-09-16T09:31:56Z | |
| dc.date.available | 2026-09-16T09:31:56Z | |
| dc.date.issued | 2025-10 | |
| dc.description.abstract | Age-related macular degeneration (AMD) is one of the leading causes of blindness in individuals over 60 years of age and is classified into two main subtypes: geographic atrophy (dry AMD) and neovascular AMD (wet AMD). Antivascular endothelial growth factor (anti-VEGF) agents are the standard treatment for neovascular AMD, although guidelines diverge regarding first-line choices. This scoping review aims to identify and characterize current scientific evidence on the use of anti-VEGF agents in the treatment of neovascular AMD. A systematic search was conducted in PubMed for observational or experimental studies published between 2020 and April 2025. Eligible studies included individuals aged ⩾60 years, reported on the use of anti-VEGF therapy for neovascular AMD, and assessed both functional (visual acuity) and morphological outcomes. Sixty-five studies met the inclusion criteria – 56 observational studies (prospective cohorts and cross-sectional designs), and nine clinical trials. Aflibercept (34%), faricimab (18%), and ranibizumab (15%) were the most commonly agents. Ranibizumab and aflibercept consistently improved visual acuity, with average gains of 7–15 ETDRS letters. Bevacizumab yielded more variable outcomes. In refractory patients, brolucizumab or faricimab showed anatomical improvements; however, brolucizumab was associated to higher risk of intraocular inflammation. The findings suggest that clinical and anatomical factors, such as persistent subretinal fluid, central retinal thickness, and initial treatment response, may help guide a more individualised selection of anti-VEGF. While ranibizumab and aflibercept remain well-established options, faricimab shows potential, in patients with suboptimal response to conventional agents. | eng |
| dc.identifier.citation | Queirós, M., Teixeira, D., Jesus, Â., Santos, M., Moreira, F., & Fernandes, S. R. (2025). ANTI-VEGF therapies in neovascular age-related macular degeneration: A scoping review of functional and morphological outcomes in older adults. 13th APLF Annual Conference, TherapeuTic advances in drug safety 16(S1), 47–48. https://journals.sagepub.com/doi/epub/10.1177/20420986251379201 | |
| dc.identifier.doi | 10.1177/20420986251379201 | |
| dc.identifier.eissn | 2042-0994 | |
| dc.identifier.issn | 2042-0986 | |
| dc.identifier.uri | http://hdl.handle.net/10400.22/32715 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | SAGE Publications | |
| dc.relation.hasversion | https://journals.sagepub.com/doi/10.1177/20420986251379201 | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.subject | Anti-VEGF | |
| dc.subject | Neovascular age-related macular degeneration | |
| dc.subject | Visual acuity outcomes | |
| dc.title | ANTI-VEGF therapies in neovascular age-related macular degeneration: a scoping review of functional and morphological outcomes in older adults | eng |
| dc.type | conference object | |
| dspace.entity.type | Publication | |
| oaire.citation.conferenceDate | 2025-10 | |
| oaire.citation.conferencePlace | Aveiro | |
| oaire.citation.endPage | 48 | |
| oaire.citation.issue | S1 | |
| oaire.citation.startPage | 47 | |
| oaire.citation.title | 13th APLF Annual Conference - TherapeuTic advances in drug safety | |
| oaire.citation.volume | 16 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |
| person.familyName | Santos | |
| person.familyName | Moreira | |
| person.familyName | Fernandes | |
| person.givenName | Marlene | |
| person.givenName | Fernando | |
| person.givenName | Sara | |
| person.identifier | 1508370 | |
| person.identifier | 2947760 | |
| person.identifier.ciencia-id | 8311-B967-31C4 | |
| person.identifier.ciencia-id | 5F16-AB92-94D0 | |
| person.identifier.ciencia-id | 1C12-D800-38A4 | |
| person.identifier.orcid | 0000-0001-5020-5942 | |
| person.identifier.orcid | 0000-0002-3452-1459 | |
| person.identifier.orcid | 0000-0001-7042-1941 | |
| person.identifier.scopus-author-id | 57110502000 | |
| person.identifier.scopus-author-id | 57203278917 | |
| relation.isAuthorOfPublication | 8ce9ee39-a4c6-46ae-99e2-49397b550f1b | |
| relation.isAuthorOfPublication | 81213e80-09a5-4655-93dc-e54199edb2fe | |
| relation.isAuthorOfPublication | 6c2ed5f0-c3fd-4559-99a3-b8d78d019b47 | |
| relation.isAuthorOfPublication.latestForDiscovery | 8ce9ee39-a4c6-46ae-99e2-49397b550f1b |